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Abstract: 
 
Objective  
To investigate the impact of residual ꞵ-cell function on continuous glucose monitor 
(CGM) outcomes following acute exercise in people with Type 1 diabetes. 
Research Design and Methods  
Thirty participants with type 1 diabetes for ≥3 years were recruited. Firstly, participants 
wore a blinded CGM for 7 days of free-living data capture. Secondly, a 3 hour mixed 
meal test, assessed stimulated C-peptide and glucagon. Peak C-peptide was used to 
allocate participants into undetectable (Cpepund <3 pmol/L), low (Cpeplow 3–200 
pmol/L) or high C-peptide groups (Cpephigh >200 pmol/L). Finally, participants 
completed 45 minutes of incline treadmill walking at 60%VO2peak followed by a further 
48 hours’ CGM capture. 
Results  
CGM parameters were comparable across groups during the free-living observation 
week. In the 12 (12hr) and 24 hours (24hr) post-exercise periods the Cpephigh group 
had significantly greater amount of time spent with glucose 3.9-10 mmol/L (12hr: 
73.5±27.6%, 24hr: 76.3±19.2%) compared to Cpeplow (12hr: 43.6±26.1%, p=0.027, 
24hr: 52.3±25.0%, p=0.067) or Cpepund (40.6±17.0%, p=0.010, 24hr: 51.3±22.3%, 
p=0.041). Time spent in hyperglycemia (12hr and 24hr glucose >10 and >13.9 mmol/L, 
p<0.05) and glycemic variability (12hr and 24hr SD, p<0.01) were significantly lower 
in the Cpephigh group compared to Cpepund and Cpeplow. Change in CGM outcomes 
from pre to 24hr post-exercise was divergent: Cpepund and Cpeplow experienced 
worsening (glucose 3.9-10 mmol/L: -9.1% and -16.2% respectively), with Cpephigh 
experiencing improvement (+12.1%)(p=0.017).  
Conclusions  
Residual ꞵ-cell function may partially explain the inter-individual variation in the acute 
glycemic benefits of exercise in individuals with type 1 diabetes. Quantifying C-peptide 
could aid in providing personalized and targeted support for exercising patients. 
Introduction:  1 
 2 
Individuals with type 1 diabetes are encouraged to regularly engage in physical activity 3 
(PA) and exercise because of many health benefits, such as reduced cardiovascular 4 
risk factors and improvements in physical fitness [1]. However, exercise can cause 5 
disruption to maintaining euglycemia, particularly when causing hypoglycemia, and 6 
can be complex to manage [2]. This may explain the lower PA levels within the type 1 7 
diabetes population compared to the general public [3].   8 
One major obstacle to providing exercise support to people with type 1 diabetes is a 9 
high inter-individual variability in the blood glucose responses to exercise [2]. Even 10 
within tightly controlled research studies that have adopted a strict inclusion criteria, 11 
recruited a homogenous cohort of participants, have standardized insulin and dietary 12 
intake and used continuous glucose monitoring (CGM) to stabilise pre-trial glucose, a 13 
large unexplained inter-individual variability in the acute glycemic responses to 14 
exercise remains [4-7]. This is despite a high intra-individual reproducibility under 15 
repeated conditions [4,5]. Indeed, outside of formal research, both clinical 16 
observations and feedback from patient support groups report potential for both an 17 
improvement and detrimental impact of regular exercise on HbA1c. Wide-ranging 18 
challenges in successfully avoiding hypoglycemia persist, despite advancement and 19 
availability of supportive strategies including CGM and patient education.  20 
Recent research has shown that even in long duration type 1 diabetes, ꞵ-cell function 21 
– as measured by C-peptide – can persist. There is some disparity within the evidence 22 
regarding the prevalence of residual ꞵ-cell function within the type 1 diabetes 23 
population, but it is estimated that between 35 and 80% of participants have detectable 24 
ꞵ-cell function at >5 years post-diagnosis [8,9]. Moreover, it is estimated that 8-16% 25 
of individuals diagnosed with type 1 diabetes as an adult have a relatively high C-26 
peptide level, above the threshold found in the Diabetes Control and Complications 27 
Trial (DCCT: >200 pmol/L) to have some clinical benefits [10], compared to 5-6% of 28 
individuals with childhood onset of diabetes [8,9,11].  29 
Evidence from recently diagnosed individuals and after islet transplantation, when 30 
consequently C-peptide levels are relatively high, demonstrates that as residual ꞵ-cell 31 
function declines, CGM parameters such as time in euglycemia (time in range 3.9-10 32 
mmol/L) and CV% worsen [12,13]. A recent paper by Rickels et al.[14] demonstrated 1 
that individuals with short-duration type 1 diabetes and very high stimulated C-peptide 2 
(>400 pmol/L) had greater time in euglycemia at rest compared to negative, low (17-3 
200 pmol/L) and intermediate (200-400 pmol/L) C-peptide groupings. How this 4 
translates to people with established, longer-duration type 1 diabetes and around 5 
exercise, is unclear. Potentially, diminished but functioning ꞵ-cells may convey some 6 
level of intrinsic glucose regulation that offers benefits under an intense metabolic 7 
stressor (including increased metabolic rate, carbohydrate oxidation and insulin 8 
sensitivity) such as exercise. Moreover, it can be hypothesized that ꞵ-cell function is 9 
associated with CGM outcomes explaining (at least in part) inter-individual variability 10 
in the exercise response. This information could be valuable for provision of targeted 11 
exercise support, based on C-peptide status. 12 
This study examined the impact of residual ꞵ-cell function on CGM outcomes after a 13 
bout of aerobic exercise in people with type 1 diabetes. We hypothesized that 14 
individuals with greater C-peptide will have increased amount of time with an interstitial 15 
glucose in euglycemia (3.9-10 mmol/L) – the primary outcome.  16 
 17 
 18 
 19 
  20 
Research Design and Methods: 1 
 2 
Participants 3 
Eligibility criteria comprised a clinical diagnosis of type 1 diabetes (primary osmotic 4 
symptoms, weight loss, hyperglycemia, ketosis, insulin initiation at diagnosis); age 18-5 
65 years with diabetes duration ≥3 years at enrolment; HbA1c <86 mmol/mol (10.0%); 6 
absence of diabetes-related complications apart from retinopathy; and stable Multiple 7 
Daily Injection (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) regimen 8 
without changes over the preceding 6 months. All participants provided written 9 
informed consent and this study was approved by the local National Health Service 10 
Research Ethics Committee (code:16/NE/0192, registry:ISRCTN50072340). 11 
Sample Size 12 
Sample size estimation was calculated using available C-peptide and CGM data 13 
previously conducted by our group [13]. Using percentage time in range 3.9–10 14 
mmol/L during a 5-day CGM capture from islet transplant recipients with stimulated C-15 
peptide >200 pmol/L (71±21%) and <150 pmol/L (45±16%). With an estimated 16 
difference of at least 10% in the primary outcome, a sample of 10 participants per 17 
group would be needed to test the null hypothesis that mean time within range (3.9-18 
10.0 mmol/L) of all groups is equal with a probability of 0.8. Type 1 error associated 19 
with this calculation is 0.05.   20 
Participant identification and recruitment 21 
Potential participants with ≥3 years duration were first identified using a home Urine 22 
C-peptide to Creatinine Ratio (UCPCR) kit [15]. Three years was used to allow a clear 23 
gap from the approximate 2 year point often referred to as the ‘honey moon’ [16]. 24 
UCPCR results were used to preliminarily allocate participants in one of three UCPCR 25 
groupings: undetectable (<0.001), low (0.001-0.19) and high (≥0.2 nmol/mmol). 26 
Supplement figure 1 has a schematic of the study recruitment numbers and protocol. 27 
Visit 1: Free-living Observational CGM Week  28 
Participants attended the Newcastle NIHR Clinical Research Facility (CRF) for 29 
insertion of a blinded CGM unit (Enlite® sensor with iProTM2 Professional CGM 30 
Medtronic Diabetes, Medtronic MiniMed, USA). During the observational free-living 1 
week, patients self-recorded insulin dosages and capillary blood glucose (CBG) 2 
concentrations. CBG were recorded ≥4 times per day for calibration purposes with 3 
sensor data retrospectively processed using CareLink software (Medtronic Diabetes). 4 
If a day’s CGM recording, from midnight to midnight, failed any of the Carelink optimal 5 
data thresholds (Valid calibrations, MAD%, Correlations)[17] or had missing data 6 
greater than 15 minutes segments, data from throughout that day were deemed sub-7 
optimal and not used. If the iProTM2 failed to collect 4 valid days of data the testing 8 
process was repeated. 9 
Visit 2: Mixed Meal Tolerance Test 10 
Participants attended the CRF at ~8.30am after an overnight fast and a cannula was 11 
inserted into an antecubital vein. Individuals were instructed to maintain their normal 12 
basal insulin regimen. A mixed meal tolerance test (MMTT) protocol was used, with 13 
participants given 240 ml of Fortisip (Nutricia, Trowbridge, UK;  360kcal, 14.4g protein, 14 
13.92g fat and 44.16g carbohydrate) to drink within 2 minutes [18]. Blood samples 15 
were drawn at baseline and every 30 minutes up to and including 180 minutes. 16 
Samples were centrifuged with plasma and serum stored at -80 °C in the Newcastle 17 
Biobank facility.  18 
Visit 3: Health screening and Maximum Exercise Test 19 
Participant height, weight (Seca 220 stadiometer / Seca 889 scales, Seca, Germany) 20 
and medical history were taken. Participants underwent a modified 12-lead resting and 21 
exercising electrocardiogram (ECG) to screen for cardiac abnormalities.  22 
A maximal graded walking treadmill (Valiant 2 CPET, Lode, Groningen, Netherlands) 23 
test (Bruce protocol [19]) was performed to determine peak oxygen uptake (VO2peak) 24 
and peak heart rate. Glycemic strategy was managed as per the guidance of Riddell 25 
et al.[2]. 26 
Visit 4: Main trial exercise bout 27 
Prior to the submaximal exercise phase, participants attended the CRF 24-48 hours 28 
before the final testing visit, to have a CGM inserted. Individuals arrived at the exercise 29 
lab at ~8.30am after an overnight fast, having been instructed to maintain their normal 30 
basal insulin regimen. If participants had a hypoglycemic event overnight prior to the 31 
study visit, the visit was rearranged, while if participants awoke with blood glucose >10 1 
mmol/L they were instructed to have a small corrective bolus of insulin upon waking 2 
(≤2 units). A carbohydrate (CHO) snack (Belvita, Mondelēz International, USA), 3 
providing 204kcal of which 31g CHO, was consumed and participants remained rested 4 
for 20 minutes. Target CBG was >7 mmol/L for the duration of the exercise, with 5 
participants given 10g of carbohydrate if CBG fell below this level. Participants walked 6 
at 60% VO2peak for 45 minutes at a comfortable stride length (7.15±3.58% gradient at 7 
5.09±0.28kph). Individual treadmill speed and gradient was calculated using VO2, 8 
speed, and gradient data from the preliminary exercise test [20].Heart rate and expired 9 
air were captured and analysed throughout (Metalyzer® 3B-R3 CPET, Cortex, Leipzig, 10 
Germany), with gradient adjusted at 10 and 30 minutes if VO2  was >10% different 11 
than target VO2. Upon completion of the exercise, participants rested for 60 minutes 12 
before being discharged from the laboratory. For the 48 hours following the exercise 13 
bout free-living interstitial glucose responses were captured and participants recorded 14 
CBG.  15 
Blood Sample analysis 16 
Samples from Visit 2 were transported to Exeter Clinical Laboratories for analysis of 17 
serum C-peptide, glucagon and auto-antibodies. C-peptide was analysed using a 18 
direct electrochemiluminescence immunoassay (E170 analyser, Roche Diagnostics, 19 
Mannheim, Germany) as described elsewhere [21]. Lower limit of detection was 3.3 20 
pmol/l with a reported intra- and inter-assay coefficient of variation of 3.3% and 4.5% 21 
[22]. Individual’s peak serum C-peptide recorded during the MMTT was used to 22 
confirm which C-peptide groups participants were sorted into; undetectable (Cpepund) 23 
<3 pmol/L, low (Cpeplow) 3–200 pmol/L and high (Cpephigh) >200 pmol/L. The high C-24 
peptide grouping was based upon the clinically significant threshold found in the DCCT 25 
[10], while the low C-peptide threshold was based upon the lower limit of detection of 26 
the assay. Serum glucagon was measured using a Glucagon ELISA (Mercodia AB, 27 
Uppsala, Sweden) on the Dynex DS2 automated platform (Dynex Technologics, 28 
Worthing, U.K) with a lower limit of detection of 1.5 pmol/L. 29 
Auto-antibody analysis was performed using ELISA assays (RSR Ltd., Cardiff, UK) on 30 
the DS2 automated platform (Dynex Technologics, Worthing, U.K) as previously 31 
reported [23]. The cut-offs for positivity were: ≥7.5 U/mL (IA-2); ≥11 U/mL (GAD65); 32 
≥65 U/mL (ZnT8) if aged < 30 years or ≥9.1 U/mL if aged >30 years. Positive result 1 
defined as above the 97.5th centile of 1,559 control participants without diabetes [23].  2 
Statistical and data analysis 3 
Data are presented as mean±standard deviation throughout unless otherwise stated 4 
with statistical significance set at p<0.05. The primary outcome was amount of time 5 
with an interstitial glucose in euglycemia (3.9-10 mmol/L) in the 24 hours post-6 
exercise. Secondary outcomes were euglycemia at 12 hours, and glycemic variability 7 
(standard deviation (SD) and coefficient of variance (CV)), time spent in hypoglycemia 8 
and time spent in hyperglycemia in the 12 and 24 hours post-exercise. CGM ranges 9 
were defined as 3.9-10 mmol/L (euglycemia), <3.9 mmol/L (hypoglycemia 1), <3.0 10 
mmol/L (hypoglycemia 2), >10 mmol/L (hyperglycemia 1), >13.9 mmol/L 11 
(hyperglycemia 2) as recommended by international consensus [24]. CV was 12 
calculated as SD divided by mean glucose.  13 
Statistically significant differences between the means of Cpepund, Cpeplow and 14 
Cpephigh were determined by one-way ANOVA with Tukey post-hoc analysis. Data 15 
were assessed for normality and outliers by Shapiro-Wilk test and boxplots, with 16 
skewed data assessed by Kruskal-Wallis H test. Pearson product-moment or 17 
Spearman's rank-order correlation were used to determine the strength and direction 18 
of a linear relationship between peak MMTT serum C-peptide and glucagon vs CGM 19 
data. GraphPad Prism 8.0.1 (San Diego, USA) and IBM SPSS Statistics (version 24, 20 
IBM, Armonk NY) software package were used to analyse the data. 21 
 22 
Results: 1 
 2 
Three participants who were initially recruited with a ‘Low’ UCPCR, subsequently 3 
demonstrated an undetectable peak serum C-peptide. Additionally, two participants 4 
with ‘Undetectable’ UCPCR subsequently showed ‘Low’ C-peptide positivity during the 5 
MMTT.  6 
Participants were allocated into three groups according to MMTT peak serum C-7 
peptide. Demographic and MMTT group data are shown in Table 1. Age, HbA1c, BMI, 8 
insulin and VO2peak were comparable between groups. However, the Cpephigh group 9 
had significantly higher age of diagnosis and shorter duration of diabetes than the 10 
Cpepund. Although C-peptide metrics differed between groups (in keeping with the 11 
study design), MMTT glucagon values were comparable. Fasting glucose was 12 
comparable at baseline of the MMTT, with the Cpephigh group having significantly lower 13 
peak and delta change compared to the Cpepund.   14 
*** INSERT TABLE 1 HERE *** 15 
 16 
Observational week 17 
Data was collected for an average 5.1±0.96 days, with no differences between groups 18 
(p=0.730). During the observational week, there were no differences between the C-19 
peptide groups in time spent in euglycemia (Figure 1A), hypoglycemia or 20 
hyperglycemia, mean glucose, SD or CV. MMTT C-peptide and glucagon values did 21 
not predict any CGM outcomes during the observational week (p>0.05)(Table 2).  22 
Laboratory phase - Exercise bout 23 
On average, participants exercised at 59.4±4.1% of their VO2peak, with no differences 24 
between the C-peptide groups (p=0.542). The Cpepund group had higher CBG on 25 
arrival (Cpepund 9.83±2.17, Cpeplow 7.96±3.11, Cpephigh 7.25±1.52 mmol/L, p=0.045), 26 
pre (Cpepund 11.42±2.76, Cpeplow 9.37±1.61, Cpephigh 8.30±1.14 mmol/L, p=0.007) 27 
and post-exercise (Cpepund 13.00±4.38, Cpeplow 9.26±4.37, Cpephigh 9.00±2.83 28 
mmol/L, p=0.048), as well on leaving the laboratory at 1 hour post-exercise (Cpepund 29 
13.34±3.21, Cpeplow 11.23±3.86, Cpephigh 9.32±2.58 mmol/L, p=0.029), compared to 30 
the Cpephigh but not the Cpeplow group. There were no incidences of hypoglycemia 31 
within the laboratory phase of the study, either during the exercise or throughout the 1 
60 minute post-exercise recovery. Six participants (1 Cpepund, 2 Cpeplow and 3 2 
Cpephigh) were given 10g of additional carbohydrates during the exercise bout as their 3 
blood glucose had dropped below 7 mmol/L. 4 
Post exercise  5 
Twelve and 24 hour post-exercise interstitial glucose responses are presented in 6 
Figure 1B+C and Table 2. The Cpephigh group spent 73.51±27.64% of the 12 hours 7 
post-exercise in euglycemia, compared to 43.58±26.07% for Cpeplow (p=0.027) and 8 
40.61±16.97% for Cpepund (p=0.010)(Figure 1.B). The Cpephigh group also had 9 
significantly less time spent in hyperglycemia (Categories 1 and 2), lower mean 10 
glucose and SD compared to Cpeplow and Cpepund (p<0.05). No difference existed 11 
between groups for time spent with CGM glucose <3.9 mmol/L (p=0.766) or <3.0 12 
mmol/L (p=0.370), although notably mean time with CGM <3.0 mmol/L was zero in the 13 
Cpephigh group.  14 
*** INSERT FIGURE 1 HERE *** 15 
 16 
Similar patterns were observed in the interstitial glucose response in the 24 hours 17 
post-exercise period, with Cpephigh having higher time in euglycemia (76.25±19.16%) 18 
than Cpepund (51.33±22.26%, p=0.041), although not statistically higher than Cpeplow 19 
(52.31±24.98%, p=0.067)(Figure 1.C). Cpephigh had significantly lower amount of time 20 
spent in hyperglycemia and reduced measures of GV compared to both Cpeplow and 21 
Cpepund. 22 
In the 24 to 48 hours following the exercise bout, the effects were largely lost with only 23 
time spent >13.9 mmol/L and SD significantly lower in the Cpephigh group compared 24 
to Cpepund and Cpeplow (Table 2. Figure 1.D). 25 
Peak stimulated glucagon was comparable across groups and did not predict time in 26 
hypoglycemia or any CGM measure post exercise (p>0.05). 27 
Delta change (Δ) in interstitial glucose parameters from the observational week to 24 28 
hours post-exercise showed significant correlations between peak C-peptide and time 29 
in euglycemia (Figure 2.A), time spent >10 mmol/L (Figure 2.C), time spent >13.9 30 
mmol/L and measures of glucose variability (Figure 2.D).  31 
 1 
*** INSERT FIGURE 2 HERE *** 2 
 3 
Participants with higher C-peptide had increased percentage time in euglycemia in the 4 
24 hours following the exercise bout compared to their free-living observational week 5 
(Δ12.11±21.54%), whereas individuals with low (Δ-16±24%, p=0.018) or undetectable 6 
(Δ-9.1±18%, p=0.073) C-peptide had reduced time in euglycemia compared to the 7 
observational week. 8 
 9 
Auto-antibody status 10 
Individual auto-antibody positivity status is displayed in Supplement table 1. Nine of 11 
the 30 participants were auto-antibody negative, including 2 participants within the 12 
Cpephigh group (duration of diabetes: 17 and 20 years, peak C-peptide 532 and 1170 13 
pmol/L, respectively). To reduce the possibility of misdiagnoses of type 2 or 14 
monogenic diabetes influencing the results, we reassessed the data excluding these 15 
participants.  16 
Between group differences within the first 12 hours post exercise mirrored those seen 17 
within the whole group analysis, with time spent in euglycemia significantly higher for 18 
Cpephigh than Cpeplow and Cpepund (p=0.023). When extended out to 24 hours the 19 
trends persisted, with clinically relevant, but not statistically significant mean 20 
differences (Cpepund 51.33±22.26, Cpeplow 52.31±24.98, Cpephigh 73.35±19.88%, 21 
p=0.093). Furthermore, the same relationships between C-peptide and Δ from the 22 
observational week to 24 hours post-exercise for euglycemia (r=0.473, p=0.041), <3.9 23 
mmol/L (r=-0.192, p=0.328), >10 mmol/L (r=-0.355, p=0.064) and CV (r=-0.432, 24 
p=0.022) exist.  25 
 26 
 27 
*** INSERT TABLE 2 HERE *** 28 
 29 
Conclusions: 1 
 2 
We investigated how residual ꞵ-cell function impacts CGM outcomes following 3 
exercise in people with type 1 diabetes. We show in the cohort studied, that under 4 
free-living conditions, time in euglycemia  is comparable despite wide-ranging residual 5 
ꞵ-cell function. Regardless, and for the first time, we demonstrate that individuals with 6 
type 1 diabetes with higher residual ꞵ-cell function (stimulated C-peptide >200 pmol/L) 7 
displayed a substantially greater amount of time spent in euglycemia in the hours 8 
following a bout of moderate intensity exercise. Furthermore, we show divergence in 9 
the impact of exercise on glycemic profiles, with high residual C-peptide associated 10 
with improved control compared with pre-exercise free-living conditions and 11 
low/absent C-peptide associated with worsened control following exercise.  12 
Results from the baseline observational free-living CGM data are similar to Rickels et 13 
al.[14]. While they demonstrated that individuals with C-peptide >400 pmol/L spent 14 
greater time in euglycemia under free-living conditions, there was no differences 15 
between the negative, low (17-200 pmol/L) and what they have defined as 16 
intermediate (200-400 pmol/L) groups.  Participants in the current study were all 17 
attending a single diabetes center. They had mainly good to moderate HbA1c, similar 18 
insulin treatment, with access to the same clinical management and education. These 19 
factors likely contributed to the comparable time in euglycemia, despite different levels 20 
of C-peptide, under these stable free-living conditions.  21 
Our primary findings that individuals with higher C-peptide had substantially increased 22 
time in euglycemia post-exercise compared to lower C-peptide individuals, in addition 23 
to the clear divergence in whether there is a positive or negative impact of exercise on 24 
CGM parameters depending on residual C-peptide status have not previously been 25 
reported. These findings were despite the cohort having comparable free-living CGM 26 
outcomes and HbA1c. We hypothesize that the endogenous insulin secretion within 27 
the Cpephigh group combined with increased insulin sensitivity following the exercise 28 
bout attenuated high blood glucose excursions. Indeed, the results from the MMTT 29 
demonstrated an attenuated glucose response within the high C-peptide group. 30 
Exercise can independently increase glucose uptake into the skeletal muscles via the 31 
redistribution of GLUT4 glucose transporters to the cell membrane [25]. A single bout 32 
of endurance exercise also increases insulin’s action [26], with sensitivity to insulin 1 
persisting up to 48 hours post exercise [27]. These mechanisms may contribute to the 2 
difficulties in maintaining time in euglycemia after exercise in those with low C-peptide, 3 
while enhancing the beneficial impact of endogenous insulin secretion within higher 4 
C-peptide individuals. 5 
Authors from previous secondary analysis of glycemic control during and after 6 
exercise have postulated that insulin resistance may play a role in the inter-individual 7 
variability [28]. As a longer duration of diabetes is associated with increased insulin 8 
resistance [29], and the Cpephigh group had a lower mean duration, this study cannot 9 
rule out the role insulin resistance plays in post-exercise glycemic control. However, it 10 
is important to note that the BMI (25.22±3.73 kg/m2), total daily insulin dose 11 
(41.77±23.40 units) and dose per kg (0.55±0.24 units/kg/day) were comparable across 12 
groups, and were not high enough to indicate insulin resistance. 13 
Avoidance of hypoglycemia, in everyday life as well as during and after exercise, is of 14 
central importance for people with type 1 diabetes. A wide range of methods, including 15 
nutritional and insulin adjustments have been reported and discussed, yet difficulties 16 
in maintaining euglycemia around exercise are prevalent [2]. Previous studies have 17 
reported that preserved ꞵ-cell function was associated with reduced self-reported 18 
hypoglycemia [30-31], however neither this study or previous have seen time spent in 19 
hypoglycemia as measured by CGM influenced by C-peptide [14]. In the current study, 20 
time spent in hypoglycemia (<3.9 and 3 mmol/L) in the post exercise period was ≥2-21 
fold less in the Cpephigh group, which may be clinically meaningful although not 22 
statistically different. Future studies should carefully consider how to most 23 
meaningfully measure hypoglycemia in free-living conditions, with a combination of 24 
CGM and diaries likely to be needed [32]. 25 
This study provides further evidence that the paradoxical glucagon secretion in 26 
response to oral ingestion is not influenced by C-peptide status, and that peak 27 
glucagon measured by these methods does not associate with time spent in 28 
hypoglycemia [14,33]. However, recent research demonstrates that during a 29 
hyperinsulinemic hypoglycemic clamp, those with persistent ꞵ-cell function have 30 
residual counter-regulatory responses to hypoglycemia including increased glucagon 31 
[34]. Additionally, there is a reduction in biochemical hypoglycemia and an increase in 32 
glucagon response to hypoglycemic clamp in C-peptide positive islet transplant 1 
recipients [16]. The α-cell’s ability to secrete glucagon in response to hypoglycemia is 2 
impaired around diagnosis of type 1 diabetes [35], with further functional losses as 3 
duration of diabetes increases [36]. It is hypothesized that functioning ꞵ-cells within 4 
the islet of Langerhans enable residual α-cell function allowing some hypoglycemia 5 
protection, although underlying mechanisms remain unclear [37]. Whether responses 6 
to a hyperinsulinemic clamp have significant impact in real world conditions requires 7 
studies such as the current one.   8 
To further understand the participants’ responses in our study, auto-antibody status 9 
was assessed to minimise the possibility of misdiagnosed diabetes impacting the 10 
results, despite a large proportion of individuals with type 1 diabetes being auto-11 
antibody negative at this longer duration of the disease [38]. Even in the high C-peptide 12 
group, the two auto-antibody negative participants met our inclusion criteria of 13 
classical presentation of T1D at diagnosis. When these participants were excluded 14 
similar patterns were observed, with residual ꞵ-cell function associated with post-15 
exercise CGM outcomes. Moreover, the same positive relationship between C-peptide 16 
and the delta change in free-living to 24 hours post-exercise euglycemia exists. 17 
Limitations of this study include participants being a single cohort from the same 18 
diabetes centre and predominantly being in moderate or good control. While the CGM 19 
capture was largely from free-living periods, the exercise bout was laboratory based 20 
with carefully managed blood glucose. It thus remains unclear whether results can be 21 
generalized to the wider exercising type 1 diabetes population.  22 
Keeping in mind the potential for residual beta-cell function to help stabilize time in 23 
euglycemia during and after exercise, future research should explore longer-term 24 
exercise and its associations with hypoglycemia. Previous studies have demonstrated 25 
that exercise can blunt counter-regulatory responses to subsequent hypoglycemia 26 
[39], and conversely, antecedent hypoglycemia can blunt hormone responses to 27 
exercise [40]. Potentially, residual beta-cell function may limit the burden of 28 
hypoglycemia by preserving some of these counter-regulatory responses to repeated 29 
bouts of physiological stress, helping facilitate effective and safe long-term exercise. 30 
Investigations into whether residual ꞵ-cell function influences the glycemic responses 31 
to differing modalities of exercise (i.e. resistance, high intensity intermittent training), 32 
as well as under a range of different insulin and nutritional strategies around exercise 33 
(i.e. fasted morning exercise) are warranted. Finally, a large long-term trial is needed 1 
to explore if C-peptide predicts HbA1c changes with exercise, as well as to explore 2 
further glycemic and cardiovascular outcomes, teasing apart whether reported 3 
improvements in diabetes complications are due to glycemic improvements and/or 4 
potentially a direct impact of C-peptide upon vasculature.  5 
In conclusion, people with type 1 diabetes who have higher residual beta-cell function 6 
show improved time in euglycemia following exercise. C-peptide may be useful in 7 
identification of patients most at risk of exercise associated dysglycemia. We show 8 
that future exercise research should consider level of C-peptide as a factor that may 9 
impact study outcomes. 10 
 11 
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 20 
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Tables: 1 
Table 1. Demographic and MMTT results for each C-peptide grouping. Data indicates 2 
mean ± SD.  3 
 4 
Brackets indicate ranges. * Significantly different to Cpepund † Significantly different to Cpeplow 5 
C-Peptide Grouping CPEPUND CPEPLOW CPEPHIGH p 
N 11 9 10  
Male/Female 5/6 6/3 5/5  
Age (Years) 40.09 ± 11.18 (26 to ‘58) 
38.67 ± 14.73 
(25 to 61) 
35.80 ± 10.98 
(18 to 52) 0.738 
Age At Diagnosis 
(Years) 
13.27 ± 4.50 
(8.00 to 24) 
16.56 ± 8.57 
(8.00 to 32.00) 
25.10 ± 8.20 * 
(13.00 to 35.00) 0.003 
Duration Of Diabetes 
(Years) 
26.82 ± 13.24 
(13.00 to 47.00) 
21.89 ± 13.34 
(9.00 to 44.00) 
10.70 ± 6.15 * 
(3.00 to 20.00) 0.015 
HbA1c (mmol/mol) 61.64 ± 10.64 (42.00 to 78.00) 
58.11 ± 7.11 
(51.00 to 74.00) 
55.40 ± 8.47 
(41.00 to 69.00) 0.297 
(%) 7.8 ± 3.1 (6.0 to 9.3) 
7.5 ± 2.8 (6.8 to 
8.9) 
7.2 ± 2.9 (5.9 to 
8.5)  
BMI (kg/m2) 25.65 ± 3.27 24.20 ± 4.13 25.67 ± 4.04 0.259 
Daily Insulin (units) 39.93 ± 15.15 47.88 ± 23.21 38.30 ± 31.23 0.242 
Insulin units/kg/day 0.54 ± 0.19 0.63 ± 0.25 0.49 ± 0.29 0.332 
Method Of Control 
(MDI/CSII) 5/6 4/5 6/4  
VO2peak 35.61 ± 7.69 (21.05 to 49.00) 
43.93 ± 9.03 
(31.80 to 58.25) 
35.67 ± 10.77 
(21.25 to 51.00) 0.194 
MIXED MEAL TOLERANCE TEST 
Peak C-Peptide 
(pmol/L) 
0.00 ± 0.00 
(0 to 0) 
42.00 ± 32.58 * (4 to 
83) 
671.70 ± 435.15 * † 
(221 to 1640) <0.001 
Median 0.00 53.00 568.50  
AUC0TO180min C-Peptide 
(pmol/L) 0.00 ± 0.00 6026 ± 4452 * 89459 ± 48095 * † <0.001 
Peak Glucagon 
(pmol/L) 14.04 ± 6.74 18.60 ± 13.49 12.45 ± 4.34 0.802 
AUC0TO180min  Glucagon 
(pmol/L) 1557 ± 905.8 2072 ± 1370 1259 ± 674.5 0.252 
Pre Glucose (mmol/L) 10.12 ± 3.38 9.55 ± 1.62 8.47 ± 3.15 0.428 
Peak Glucose 
(mmol/L) 21.91 ± 2.75 20.03 ± 2.34 17.74 ± 3.59 * 0.016 
Δ Pre to Peak Glucose 
(mmol/L) 11.76 ± 2.77 10.48 ± 2.12 9.27 ± 3.02 * 0.045 
Auto-Antibody 
Positivity 6/11 7/9 8/10  
 Table 2. One-way ANOVA results for the CGM outcomes of each C-peptide grouping at different time points. Data is mean ± SD 
 
 
 
* indicates significantly different to Cpepund  † indicates significantly different to Cpeplow  
 
 
 Free-living Observational Week 12 Hours Post Exercise 24 Hours Post Exercise 
 Cpepund Cpeplow Cpephigh p Cpepund Cpeplow Cpephigh p Cpepund Cpeplow Cpephigh p 
< 3 
mmol/L 0.7 ± 1.4 1.3 ± 1.9 0.9 ± 1.2 0.710 0.7 ± 2.4 3.0 ± 8.4 0.0 ± 0.0 0.284 1.3 ± 3.7 
5.3 ± 
15.4 0.5 ± 1.5 0.773 
< 3.9 
mmol/L 3.5 ± 3.2 8.7 ± 9.7 5.7 ± 5.4 0.540 3.6 ± 5.1 5.9 ± 9.1 1.9 ± 3.2 0.586 3.2 ± 5.1 
9.3 ± 
16.2 4.1 ± 9.8 0.471 
> 10 
mmol/L 
36.1 ± 
14.7 
22.8 ± 
10.0 
30.2 ± 
16.3 0.129 
55.8 ± 
17.5 
50.5 ± 
30.3 
24.6 ± 
27.6* 0.015 
45.5 ± 
23.5 
38.4 ± 
24.8 
19.7 ± 
19.6 * 0.043 
> 13.9 
mmol/L 8.8 ± 5.9 4.3 ± 3.4 6.8 ± 8.6 0.206 
20.2 ± 
15.7 
23.6 ± 
18.1 
2.3 ± 
6.0*† 0.001 
12.0 ± 
10.2 
19.1 ± 
20.9 
1.3 ± 
3.2*† 0.001 
Mean 9.1 ± 1.2 7.8 ± 1.3 8.5 ± 1.6 0.149 10.7 ± 1.6 
10.7 ± 
2.9 8.2 ± 1.6* 0.006 9.8 ± 1.7 9.6 ± 3.0 7.7 ± 1.5 0.065 
SD 3.2 ± 0.6 3.0 ± 0.6 3.1 ± 0.6 0.604 3.4 ± 1.2 3.7 ± 1.0 2.0 ± 1.0*† 0.003 3.0 ± 0.9 3.8 ± 1.0 
2.0 ± 
0.7*† <0.001 
CV (%) 36.7 ± 7.6 
38.2 ± 
7.3 
36.5 ± 
6.0 0.848 
32.5 ± 
11.5 
36.8 ± 
14.2 
24.8 ± 
9.9 0.098 
31.9 ± 
10.8 
42.1 ± 
15.4 
26.2 ± 
9.6 † 0.025 
Figure legends: 
 
 
Figure 1. Group mean±SD and individual data points for time spent in a euglycemic range 3.9 to 10 
mmol/L during (A) the observational free-living week, (B) 12 hours post submaximal exercise bout, (C) 
24 hours post submaximal exercise bout, (D) between 24 and 48 hours post submaximal exercise bout. 
Red circles = Cpepund (n=11), Orange circles = Cpeplow (n=9), Green circles = Cpephigh (n=10). * 
indicates significantly different to Cpepund, # indicates significantly different to Cpeplow. 
 
 
 
 
Figure 2. Scatter plots displaying linear relationships between peak serum C-peptide vs the delta 
change in glycemic control measures from the free-living observational week to the 24 hours post 
exercise (n = 30). (A)  Delta change in the percentage of time spent in 3.9 to 10 mmol/L, (B) Delta 
change in the percentage of time spent <3.9 mmol/L, (C) Delta change in the percentage of time spent 
>10 mmol/L and (D) Delta change in the CV%. * indicates significant correlation. 
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